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Background. Triple nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the World
Health Organization as first-line regimen in treatment-naive HIV-2–infected patients. However, ritonavir-boosted
protease inhibitor (PI/r)–containing regimens are frequently prescribed. In the absence of previous randomized
trials, we retrospectively compared these regimens in observational cohorts.
Methods. HIV-2–infected patients from 7 European cohorts who started triple NRTI or PI/r since January 1998
were included. Piecewise linear models were used to estimate CD4 cell count and plasma HIV-2 RNA level slopes,
differentiating an early phase (until end of month 3) and a second phase (months 4–12). On-treatment analyses
censored data at major treatment modification and systematically at month 12.
Results. Forty-four patients started triple NRTI therapy and 126 started PI/r therapy. Overall, the median CD4
cell count was 191 cells/mm3 and the median plasma HIV-2 RNA level was $2.7 log10 copies/ml in 61% of the
patients at combination antiretroviral therapy (cART) initiation; the median duration of the first cART was 20
months, not differing between groups. PI/r regimens were associated with better CD4 cell count and HIV-2 RNA
level outcomes, compared with NRTI regimens. Estimated CD4 cell count slopes were 16 and 112 cells/mm3/
month during the early phase (P 5 .22), and 260 cells/mm3/year versus 176 cells/mm3/year during the second
phase (P5 .002), for triple NRTI and PI/r, respectively. Estimated mean HIV-2 RNA levels at month 12 in patients
with detectable viremia at cART initiation were 4.0 and 2.2 log10 copies/ml, respectively (P 5 .005).
Conclusions. In this observational study, PI/r-containing regimens showed superior efficacy over triple NRTI
regimens as first-line therapy in HIV-2–infected patients.
Although ultimately leading to AIDS and death, HIV-2
is associated with a slower T CD41 lymphocyte de-
pletion [1, 2], a lower viral load at comparable CD4 cell
counts [1, 3, 4], and a poorer CD4 cell recovery after
treatment initiation in naı¨ve patients [1, 5], compared
with HIV-1.
Because of the limitation of the epidemic and the
fewer treatment options because of natural resistance to
enfuvirtide and nonnucleoside reverse-transcriptase
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inhibitors (NNRTI) [6, 7], no randomized clinical trial has
assessed the efficacy of specific combination antiretroviral
therapies (cART) in treatment-naı¨ve HIV-2–infected patients.
Available data regarding nucleoside reverse-transcriptase in-
hibitors (NRTIs) and protease inhibitors (PIs) are provided by
small observational studies, evaluating first-generation anti-
retrovirals and showing no difference between drugs [1, 5, 8–10].
Current World Health Organization (WHO) treatment
guidelines for HIV-2 infection recommend triple NRTI regi-
mens as first-line cART [11]. PI in an initial treatment regimen
would essentially rule out second-line options in areas with
limited access to cART. This is important when considering that
most HIV-2–infected individuals are living in sub-Saharan Af-
rican countries, where tuberculosis is highly prevalent, with
available rifamycin curative therapy limited to rifampicin, which
interacts with PIs.
However, recent noncomparative studies have suggested
better immunological and virological responses to ritonavir-
boosted PI-containing cART in antiretroviral-naı¨ve HIV-2–
infected patients [12–14]. Furthermore, in vitro phenotypic
susceptibility studies of HIV-2 to PI have shown similar half
maximal inhibitory concentration, compared with those
reported with HIV-1 for ritonavir-boosted darunavir, lopi-
navir, and saquinavir [15]. On the basis of these ob-
servations, we investigated whether PI/r-containing cART
was associated with better immunological and virological
responses, compared with triple NRTI regimens, as first-line
therapy in HIV-2–infected patients, regardless of the level of
immunodeficiency at treatment initiation, in a large Euro-
pean collaboration.
METHODS
Study Population
ACHIEV2E (http://etudes.isped.u-bordeaux2.fr/achiev2e/) was
established in 2005 as a collaboration of 15 observational cohort
studies in 10 European countries, Gambia, and North America.
Adult patients included in the analysis had a confirmed
HIV-2 infection (HIV-1 and HIV-2 dually infected patients
were not included) and started triple NRTI or PI/r (defined
as $3 antiretrovirals) as their first-line regimen from 1 January
1998 through 20 June 2008 (when data were merged).
For each individual, follow-up began on the date of cART
initiation and ended on the date of the last recorded CD4 cell
count.
Seven cohorts participated in the present analysis: the Bel-
gium and Luxemburg HIV-2 Database (n5 16); the ANRS CO5
HIV-2 cohort, France (n 5 145); a cohort from the Section of
Infectious Diseases at the ‘‘L. Sacco’’ Hospital in Milan, Italy (n
5 3); the ATHENA cohort in the Netherlands (n 5 35); the
Santa Maria HIv2 Cohort in Portugal (n 5 29); the Spanish
HIV-2 cohort (n5 9); and the Swiss HIV Cohort Study (n5 5).
Each cohort submitted information, using a standardized data
format (ie, the HIV Collaboration Data Exchange Protocol)
[16], to the coordinating data center at the Bordeaux School of
Public Health, France. Data collected included patient de-
mographic characteristics, ART, CD4 cell counts and percen-
tages, HIV-2 RNA level, AIDS, and deaths. The coordinating
data center ensured adherence to strict quality-assurance
guidelines and performed data quality checks.
Markers and End Point Definition
In each of the 7 cohorts, CD4 cell counts were measured using
flow cytometry, but different plasma HIV-2 RNA quantification
assays were used [17]. Because each assay had a different
threshold of detectability (1.7–2.7 log10 copies/mL), the highest
threshold was taken into account. Furthermore, the best
reproducibility was achieved for plasma RNA values above this
threshold [17].
All CD4 cell count and plasma HIV-2 RNA level measurements
between treatment initiation and month 12 were taken into ac-
count to estimate the immunovirological response. In addition,
treatment success at month 12 (61.5) was defined as an increase
in CD4 cell count of$50 cells/mm3 from treatment initiation, in
conjunction with undetectable plasma RNA in the absence of
progression to AIDS, death, or major treatment modification (ie,
switch from triple NRTI or PI/r to another cART).
Statistical Analysis
The changes in CD4 cell counts and plasma HIV-2 RNA level after
cART initiation were studied using 2-phase linear mixed models
in which data were censored for major treatment modification or
after 12 months of treatment, whichever came first. The date of
first cART initiation was considered as baseline. Plasma HIV-2
RNA level changes were estimated in patients with detectable
values at baseline. Trends in the evolution of markers were fitted
using 2 slopes: one for the early change (0–3 months, in unit/
month) and a second for the long-term trend (4–12 months, in
unit/year). The correlation between individual baseline value(s)
and the subsequent slope(s) was handled through the un-
structured covariance matrix of random effects. We performed
a secondary analysis stratified by baseline CD4 cell count with use
of a threshold of 200 cells/mm3. Left-censoring of plasma viral
load because of undetectable values was taken into account by
imputing half the value of the assay’s threshold of detectability. A
sensitivity analysis was conducted among patients treated with
currently recommended regimens: 3 NRTI (lamivudine [3TC],
zidovudine [AZT], and abacavir or tenofovir) or PI/r (lopinavir,
saquinavir, or darunavir) [11, 18, 19].
Comparisons of proportions were performed using Fisher’s
exact tests. Data analyses were conducted using SAS, version 9.1
(SAS Institute).
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RESULTS
Overall, 242 HIV-2–infected adults were included in the data-
base. Of these, 72 patients were excluded from subsequent
analyses for the following reasons: 56 patients received a non-
boosted PI-containing regimen, 15 received NNRTI-based
cART, and 1 patient was treated with an enfuvirtide-containing
regimen. Of the 170 patients included in the analysis, 44 (26%)
received a triple NRTI regimen and 126 (74%) were treated with
PI/r. The vast majority (72%) of patients treated with 3 NRTIs
received a combination of abacavir, AZT and 3TC. In patients
treated with PI/r, 61% received lopinavir, 14% received in-
dinavir, and 13% received saquinavir (Table 1). Backbone reg-
imens were a combination of AZT and 3TC in 79 patients
(63%), whereas tenofovir was prescribed in 21 patients (17%; in
association with emtricitabine in 11 patients [9%]). As shown in
Table 1, 33 patients (75%) treated with 3 NRTIs and 93 (74%)
treated with PI/r were selected for the sensitivity analysis in-
cluding only currently recommended regimens.
Patients treated with 3 NRTIs did not differ from those re-
ceiving PI/r with regard to sex, age, mode of infection, and
history of AIDS (Table 2). The proportion of patients origi-
nating from Africa was higher among those treated with PI/r
than those treated with a triple NRTI regimen and patients
treated with PI/r tended to have a more advanced infection at
treatment initiation, as indicated by a higher proportion of
plasma HIV-2 RNA values .2.7 log10 copies/mL and a lower
median CD4 cell count, although these differences were not
statistically significant.
The median duration of first-line cART was 19 months (in-
terquartile interval [IQR], 7–40 months) in patients receiving 3
NRTIs and 20 months (IQR, 11–34 months) in patients treated
with PI/r. A major treatment modification during the first 12
months of treatment was reported in 10 patients (23%) treated
with 3 NRTIs and in 13 patients (10%) treated with PI/r. Rea-
sons were unknown except for 2 patients treated with a triple
NRTI regimen that experienced virological failure (threshold
variable across participating centers) and 3 patients treated with
PI/r, 2 of whom experienced toxicity issues and another who
became pregnant.
Virological Response
Sixty-seven patients with detectable plasma RNA values at
baseline were included in the estimations of plasma HIV-2 RNA
level changes (Figure 1). A total of 229 plasma HIV-2 RNA
measurements were available, with a median number of 3 (IQR,
2–3) for patients treated with 3 NRTIs and 4 (IQR, 3–5) for
patients treated with PI/r. During the first 3 months of treat-
ment, the estimated decrease in HIV-2 RNA values did not differ
in patients treated with 3 NRTIs and those treated with PI/r
(P 5 .77). From month 4 through month 12, plasma RNA
values remained low in patients treated with PI/r (20.002 log10
copies/mL/year) and increased in patients treated with 3 NRTIs
(11.6 log10 copies/mL/year), although the difference between
slopes was not statistically significant (P 5 .12). These changes
resulted in estimated plasma HIV-2 RNA values at month 12
being higher in patients treated with 3 NRTIs than in those
treated with PI/r (4.0 vs 2.2 log10 copies/mL; P 5 .005).
Only 9 patients treated with 3 NRTIs and 38 treated with PI/r
in the subset with detectable plasma RNA values at baseline
could be included in the sensitivity analysis restricted to patients
given recommended regimens only, and too few RNA meas-
urements were available to use a 2-phase linear mixed model.
However, on the basis of observed data, 1 patient (11%) had
sustained undetectable RNA values during months 3–12 among
those who received 3 NRTIs, compared with 30 (79%) among
those who received PI/r.
In patients with undetectable baseline plasma HIV-2 RNA, 1
(8%) of 12 treated with a triple NRTI regimen and 1 (3%) of 31
patients treated with PI/r had at least 1 subsequent detectable
HIV-2 RNA value within the first 12 months of treatment.
Immunological Response
Overall, 158 patients were included in the estimation of CD4 cell
count changes (Figure 2); the other 12 patients had no CD4 cell
count measurements available. A total of 669 CD4 cell count
measurements were available, with a median number of 6 (IQR,
4–8) for patients treated with 3 NRTIs and 6 (IQR, 4–10) for
patients treated with PI/r. During the first 3 months of treatment,
the estimated CD4 cell count change did not differ significantly
Table 1. Description of the First-Line cART Prescribed in
Treatment-Naive HIV-2–Infected Patients: The ACHIEV2E Collabo-
ration, 1998–2008
cART N (%)
3 NRTI
abacavir 1 lamivudine 1 zidovudine 32 (73)
tenofovir 1 lamivudine 1 zidovudine 1 (2)
didanosine 1 lamivudine 1 zidovudine 3 (7)
didanosine 1 lamivudine 1 stavudine 3 (7)
abacavir 1 didanosine 1 stavudine 2 (5)
tenofovir 1 lamivudine 1 abacavir 1 (2)
tenofovir 1 lamivudine 1 stavudine 1 (2)
didanosine 1 lamivudine 1 tenofovir 1 (2)
Ritonavir-boosted PI
Lopinavir 76 (61)
Saquinavir 16 (13)
Darunavir 1 (1)
Indinavir 18 (14)
Atazanavir 8 (6)
fos-amprenavir 7 (5)
NOTE. Bold: treatment recommended in antiretroviral-naive HIV-2–
infected patients in current guidelines.
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between patients treated with 3 NRTIs and those treated with PI/r
(P5 .24). Beyond 3 months of treatment, the estimated CD4 cell
count decreased in patients treated with 3 NRTIs and increased in
those treated with PI/r (-60 vs 176 cells/mm3/year; P 5 .002).
These changes resulted in estimated CD4 cell counts at month 12
being lower in patients treated with 3 NRTIs than in patients
treated with PI/r (191 vs 327 cells/mm3; P 5 .001).
The difference in estimated CD4 cell counts at month 12
between patients treated with 3 NRTIs and those treated with
PI/r remained statistically significant after adjustment for
geographical origin (P5 .0009) or for baseline HIV-2 RNA level
(P 5 .05). Among patients originating from Africa, the
estimated CD4 cell count at 12 months was 320 cells/mm3
(3 NRTIs), compared with 176 cells/mm3 (PI/r), and among
patients with undetectable RNA value at treatment initiation, it
was 354 cells/mm3 (3 NRTIs), compared with 242 cells/mm3
(PI/r).
Immunological response appeared to be different after 3
months, regardless of baseline CD4 cell counts. In patients with
a baseline CD4 cell count $200 cells/mm3 (Figure 3.A), the
estimated change was 299 cells/mm3/year (95% confidence
interval [CI],2201 to 4) among patients receiving a triple NRTI
regimen, compared with 152 cells/mm3/year in patients re-
ceiving PI/r (95% CI, 211 to 119; P 5 .02). The same trends
were observed in patients with a baseline CD4 cell count ,200
cells/mm3 (Figure 3.B), although the difference according to
treatment regimens was not statistically significant (P5 .56 for
the months 0–3 and P5 .26 for months 4–12).
When the analysis was restricted to recommended regimens
only (sensitivity analysis), the baseline estimated CD4 cell count
did not differ between patients treated with 3 NRTIs (227 cells/
mm3; 95% CI, 163–291 cells/mm3) and those treated with PI/r
(238 cells/mm3; 95% CI, 201–275 cells/mm3; P 5 .77). During
the first 3 months of treatment, the estimated CD4 cell count
change did not differ significantly between patients treated with
3 NRTIs (13 cells/mm3/month; 95% CI, 27 to 13 cells/mm3/
month) and patients treated with PI/r (113 cells/mm3/month;
95% CI, 7–19 cells/mm3/month; P 5 .09). Beyond 3 months of
treatment, the estimated CD4 cell count slope was 2122 cells/
mm3/year (95% CI, -139 to 51 cells/mm3/year) in patients
treated with 3 NRTIs and188 cells/mm3/year (95% CI, 43–134
cells/mm3/year) in those treated with PI/r (P 5 .01). This evo-
lution resulted in lower estimated CD4 cell counts at month 12
in patients treated with 3 NRTIs, compared with those treated
with PI/r: 344 cells/mm3 (95% CI, 298–390 cells/mm3) versus
204 cells/mm3 (95% CI, 118–290 cells/mm3; P 5 .005).
Only 106 patients (62%; 21 treated with 3 NRTIs and 85 with
PI/r) had available data at month 12 (61.5). The observed success
rate was 10% among patients treated with 3 NRTIs and 55%
among those treated with PI/r (P , .001). Five patients (26%)
treated with 3 NRTIs and 50 (67%) treated with PI/r experienced
an increase in CD4 cell count of at least 50 cells/mm3 together with
undetectable plasma RNA at month 12 (P 5 .003).
None of the patients died during the first 12 months of
treatment. One patient (2%) receiving a triple-NRTI regimen
experienced progression to AIDS (tuberculosis) 5 months after
Table 2. Main Characteristics of Treatment-Naive HIV-2–Infected Patients Starting a First-Line Triple-NRTI Regimen or PI/r-Containing
cART: The ACHIEV2E Collaboration, 1998–2008
Overall
(n 5 170)
PI/r
(n 5 126)
3 NRTI
(n 5 44) Pb
At treatment initiation
Male gender N (%) 87 (51) 64 (51) 23 (52) 0.67
Age $ 45 years N (%) 90 (53) 64 (51) 26 (59) 0.38
Median [IQR] 45.6 [38.5–52.2] 45.3 [37.5–51.8] 46.9 [40.4–54.6] 0.45
Infection through
heterosexual contact
N (%) 139 (82) 104 (83) 35 (80) 0.65
Originating from Africa N (%) 128 (75) 100 (79) 28 (64) 0.04
AIDS before cART initiation N (%) 36 (21) 28 (22) 8 (18) 0.67
Plasma HIV-2 RNA (log10 copies/ml) N (%) $2.7a 67 (61) 56 (64) 11 (48) 0.16
(n 5 110 with available data) Median [IQR]
for detectable
values
4.0 [3.4–4.6] 4.0 [3.4–4.6] 4.0 [2.9–4.6] 0.64
CD4 count (cells/mm3)
(n 5 134 with available data)
Median [IQR] 191 [90–275] 170 [72–275] 216 [150–287] 0.21
During follow-up
Duration of first line cART Median [IQR] 20 [8–36] 20 [11–34] 19 [7–40]
Major treatment modifications N (%) 23 (14) 15 (12) 8 (18)
NOTE. IQR: Inter-quartile range.
a The highest threshold of detectability was taken into account to define detectable and undetectable RNA values.
b Comparison of patients treated with ritonavir-boosted PI based regimen and those receiving a 3-NRTI cART.
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Figure 2. Estimated CD4 cell count changes with 95% confidence interval in treatment-naive HIV-2–infected patients starting a first-line triple-NRTI
regimen or PI/r-containing cART (n 5 158). The ACHIEV2E collaboration, 1998–2008. 1st slope (M0–M3): 112 cells/mm
3/month in patients treated
with a PI/r-containing cART; 16 cells/mm3/month in those treated with 3 NRTIs (P 5 .24). 2nd slope (M3–M12): 260 cells/mm3/year in patients
treated with a PI/r-containing cART; 176 cells/mm3/month in those treated with 3 NRTIs (P5 .002). M12 estimates: 327 cells/mm3 in patients treated
with a PI/r-containing cART; 191 cells/mm3 in those treated with 3 NRTIs (P 5 .001).
Figure 1. Estimated HIV-2 RNA changes with 95% confidence interval in treatment-naive HIV-2–infected patients starting a first-line triple-NRTI regimen
or PI/r-containing cART, with detectable values at treatment initiation (n 5 67). The ACHIEV2E collaboration, 1998–2008. 1st slope (M0–M3): 20.3 log10
copies/mL/month in patients treated with a PI/r-containing cART; 20.2 log10 copies/ml/month in those treated with 3 NRTIs (P 5 .77). 2nd slope
(M3–M12):20.002 log10 copies/mL/month in patients treated with a PI/r-containing cART;11.6 cells/mm3/month in those treated with 3 NRTIs (P5 .12).
M12 estimates: 2.2 log10 copies/mL in patients treated with a PI/r-containing cART; 4.0 log10 copies/mL in those treated with 3 NRTIs (P 5 .005).
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Figure 3. Estimated CD4 cell count changes with 95% confidence interval in treatment-naive HIV-2–infected patients starting a first-line triple-NRTI
regimen or PI/r-containing cART, with$200 CD4 cell/mm3 at treatment Initiation (A, n5 71) or with,200 CD4 cell/mm3 at treatment initiation (B, n5
63). The ACHIEV2E collaboration, 1998–2008. A,$200 CD4 cell/mm
3 at treatment initiation 1st slope (M0–M3):19 cells/mm3/month in patients treated
with a PI/r-containing cART;15 cells/mm3/month in those treated with 3 NRTIs (P5 .45). 2nd slope (M3–M12):152 cells/mm3/year in patients treated
with a PI/r-containing cART;299 cells/mm3/month in those treated with 3 NRTIs (P5 .02). M12 estimates: 451 cells/mm3 in patients treated with a PI/r-
containing cART; 236 cells/mm3 in those treated with 3 NRTIs (P , .001). B,,200 CD4 cell/mm3 at treatment initiation 1st slope (M0–M3): 114 cells/
mm3/month in patients treated with a PI/r-containing cART; 19 cells/mm3/month in those treated with 3 NRTIs (P 5 .56). 2nd slope (M3–M12): 180
cells/mm3/year in patients treated with a PI/r-containing cART;212 cells/mm3/month in those treated with 3 NRTIs (P5 .26). M12 estimates: 228 cells/
mm3 in patients treated with a PI/r-containing cART; 156 cells/mm3 in those treated with 3 NRTIs (P 5 .2).
1262 d CID 2011:52 (15 May) d HIV/AIDS
treatment initiation. Patients who progressed to AIDS were 9
(7%) in those treated with PI/r (cytomegalovirus infections [2],
recurrent bacterial pneumonia [1], candidiasis [1], toxoplas-
mosis [1], cryptococcosis [1], pneumocystosis [1], HIV wasting
syndrome [1], and unknown [1]) within a median delay of 2
months (range, 0.5–7.5 months) after treatment initiation.
DISCUSSION
In this large collaborative analysis comparing the immunological
and virological response to PI/r with that to triple NRTI regi-
mens among ART-naive HIV-2–infected patients followed up in
developed countries, we showed better viral suppression and
higher CD4 cell recovery associated with PI/r than with a triple
NRTI regimen. This result was observed regardless of geo-
graphical origin or baseline HIV-2 RNA values and even in
patients with baseline CD4 cell counts .200 cells/mm3. A
subgroup analysis including only patients treated with currently
recommended cART (126; 74%) yielded the same favorable
trend for those initially treated with PI/r regimens. A combined
end point reflecting successful clinical, therapeutic, virological,
and immunological measurements at month 12 showed supe-
riority of PI/r over triple NRTI regimens.
There are several limitations to our analysis. Patients were not
randomized to receive one regimen or the other; thus, there were
differences between the 2 patient groups at baseline. Although
we adjusted for geographical origin and baseline plasma HIV-2
RNA level, a bias due to unmeasured confounding might still
remain. Nevertheless, because patients receiving a PI/r regimen
had markers of more advanced disease at baseline, this bias
would lead to underestimate rather than overestimate the dif-
ference between both regimens. No data on adverse events were
available. Reasons for major treatment modifications could have
provided reasonable information on this matter, but we were
not able to collect this information from the participating co-
horts. However, major treatment modifications were rather
uncommon during the 12-month study period, and we believe
that the benefit-to-risk ratio remained in favor of PI/r over 3
NRTI regimens in HIV-2–infected patients. No data on adher-
ence were available in this retrospective study. A higher pill
burden (.10 per day) has been associated with a poorer
adherence [20, 21]. Because PI/r regimens involve a higher
pill burden than triple NRTI regimens used in our study, lack
of adherence is expected to occur more frequently with PI/r
and to jeopardize the response mainly in that group, again
reinforcing our conclusion. Of note, none of the antiretroviral
regimens considered in our study necessitated .10 pills per
day. Another limitation is the lack of a longer follow-up period
and sufficient power to investigate clinical outcomes. However,
CD4 cell counts and plasma HIV-2 RNA levels are recognized
as major predictors of clinical progression in HIV-2 infection
[3, 22, 23], and we may rely on our conclusion showing
a superiority of PI/r over triple NRTI regimens based on these
surrogate markers.
To our knowledge, our study was the first to evaluate the
efficacy of PI/r in comparison with triple NRTI regimens, since
the latter regimens have been recommended by 2010 WHO
guidelines as first-line cART in HIV-2–infected patients [11].
Our results are in line with previous noncomparative observa-
tional studies in treatment-naive HIV-2–infected patients: poor
immunological and virological responses to triple NRTI regi-
mens [8, 14] and good immunological and virological responses
to PI/r-containing cART [12, 14].
A large proportion of HIV-2–infected patients in our study
had undetectable plasma RNA at treatment initiation, even with
low CD4 cell counts. This highlights the importance of taking
into account CD4 cell count changes and plasma HIV-2 RNA
levels to adequately evaluate treatment responses in HIV-2–in-
fected patients [24]. In our study, the coherence between viro-
logical and immunological responses is in favor of a higher
effectiveness of PI/r, compared with triple NRTI regimens, in
treatment-naive HIV-2–infected patients. Indeed, in patients
receiving a triple NRTI regimen, the poor immunological re-
sponse beyond 3 months of treatment was often observed to-
gether with an increase in plasma HIV-2 RNA values during the
same period. In contrast, in patients treated with PI/r, the sus-
tained CD4 cell count increase was generally supported by
sustained viral suppression.
In vitro phenotypic susceptibility studies have reported a full
activity of all NRTIs (including zidovudine, lamivudine, and
abacavir) against wild-type ROD and EHO HIV-2 isolates [25].
The difference in viro-immunological response observed be-
tween patients receiving a triple-NRTI regimen and those treated
with PI/r might be explained by the resistance mutation profile
of HIV-2. Indeed, HIV-2 displays NRTI-resistance pathways
different from those in HIV-1 [26, 27]. Mutations Q151M
(1/2V111I) and K65R develop more frequently in HIV-2 than
in HIV-1 and are the main NRTI resistance pathways [28–30].
The Q151M mutation, together with K65R or M184V, is suffi-
cient to confer high-level resistance to both lamivudine and zi-
dovudine, the most frequently prescribed NRTIs in our study.
Furthermore, the combination of K65R, Q151M, and M184V
mutations confers classwide NRTI resistance [27]. M184V/I
appears at treatment failure in patients treated with lamivudine-
emtricitabine and has been reported to occur in vitro within 6
weeks [31]. Our results are consistent with these observations
even if no resistance data are available yet to establish the role of
resistance mutations in response to both triple NRTI regimens
and PI/r. A recent study has also increased concerns about the
risk of transmission of drug-resistant HIV-2 strains [14], further
emphasizing the need for prescribing the most potent first-line
ART in HIV-2–infected patients [32].
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The vast majority (61%) of patients treated with a PI/r-
containing cART in our study received lopinavir, and very few
were treated with other potent PI/r regimens that have shown
promising results in vitro against HIV-2, such as saquinavir or
darunavir [15]. Further research is needed to evaluate the optimal
cART regimen for treatment-naı¨ve patients with earlier HIV-2-
infection, at best through a randomized clinical trial [24, 33].
In the mean time, our results represent the best evidence to
date for the treatment of ART-naive HIV-2–infected patients
and suggest that PI/r-containing cART should be considered as
first-line ART, even when CD4 cell counts are .200 cells/mm3.
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